# Orexo

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/orexo).

## Overview

Orexo is a Swedish pharmaceutical company focused on developing, manufacturing, and commercializing proprietary drug products and drug-delivery technologies. Its portfolio includes marketed medicines such as Zubsolv, Abstral, Edluar, vorvida, and MODIA, alongside the AmorphOX powder-based delivery platform and related development collaborations.

## Products & services

• Prescription medicines: Zubsolv, Abstral, Edluar
• Digital therapeutics: vorvida, MODIA
• Drug-delivery platform: AmorphOX
• Drug development and formulation partnerships
• Manufacturing and supply of pharmaceutical products

- **Prescription medicines** (55%) — Branded pharmaceutical products sold through commercial and partner channels.
- **Drug-delivery technology** (20%) — AmorphOX platform and related formulation capabilities licensed or partnered with others.
- **Digital therapeutics** (5%) — Software-based products used to support treatment and patient engagement.
- **Development and collaboration revenue** (20%) — Revenue from partnering, formulation work, and related development services.

- Prescription medicines: Zubsolv, Abstral, Edluar
- Digital therapeutics: vorvida, MODIA
- Drug-delivery platform: AmorphOX
- Drug development and formulation partnerships
- Manufacturing and supply of pharmaceutical products

## Customers

Orexo sells to wholesalers, commercial partners, and other counterparties involved in pharmaceutical distribution and development. Its end markets include patients treated for opioid dependence, acute pain, and other therapeutic areas addressed by its branded products and platform-based collaborations.

- **Pharmaceutical wholesalers** (primary) — Buy finished medicines for downstream distribution to pharmacies and healthcare channels.
- **Commercial partners** (primary) — License or collaborate on AmorphOX formulations and related product development.
- **Patients and prescribers** (secondary) — Use Orexo-branded therapies such as Zubsolv, Abstral, and Edluar through the healthcare system.
- **Digital health users** (emerging) — Adopt vorvida and MODIA for treatment support and behavior-focused care.
- **Research and clinical partners** (secondary) — Support clinical trials, formulation work, and product development programs.

- Wholesalers that distribute prescription products to pharmacies
- Commercial partners that license or co-develop AmorphOX-based products
- Patients and prescribers in opioid dependence and pain markets
- Healthcare channels using digital therapeutics for treatment support
- CROs and development partners involved in clinical programs

## Geography

Orexo’s revenue is concentrated in the US and Europe, with the 2025 note showing EU & UK as the largest market and the US as a smaller but important market. The company also has rest-of-world sales, reflecting a broader international footprint for selected products and partnerships.

- **EU & UK** (87.3%)
- **US** (3.8%)
- **Rest of the world** (9.2%)

- EU & UK is the largest reported revenue market
- The US remains an important commercial market for Orexo products
- Rest of world sales indicate selective international reach
- Currency exposure is meaningful because revenues and costs are partly USD-based
- Geography matters because regulation and reimbursement vary by market

## Strategy

Orexo’s strategy centers on innovation in drug formulation and on expanding the AmorphOX platform through partnerships and collaborations. The company also emphasizes proprietary products, patent protection, and internal development capabilities to create differentiated therapies and extend the reach of its technology.

- **Expand AmorphOX partnerships** (medium-term) — Partnerships can scale the platform across more molecules and indications without relying only on internal commercialization.
- **Advance proprietary product innovation** (medium-term) — New formulations and products support differentiation and extend the company’s commercial base.
- **Strengthen IP and patent protection** (long-term) — Intellectual property helps defend product value and supports long-term partnering economics.

- Expand AmorphOX through strategic collaborations
- Use proprietary formulation science to create new products
- Protect inventions with patents and IP strategy
- Develop products internally while partnering selectively
- Broaden therapeutic use cases and routes of administration

## Risks

Orexo faces typical pharmaceutical risks around regulation, clinical development, product quality, and supply chain reliability, plus IT and cyber risks tied to data and operations. Its revenue base also depends on reimbursement, pricing deductions, and partner execution, while foreign exchange and liquidity management matter because the business operates internationally and carries financial obligations.

- **Regulatory and political changes** [high] — Drug development and commercialization depend on changing healthcare rules and approval standards.
- **Clinical trial execution risk** [high] — Protocol deviations, safety incidents, or GCP noncompliance can delay programs and damage credibility.
- **Supply chain and manufacturing risk** [high] — Dependence on suppliers and contract manufacturing can create quality or continuity issues.
- **IT and cyber security risk** [medium] — Data breaches, malware, phishing, and hardware failures can disrupt operations and expose sensitive information.
- **Foreign exchange risk** [medium] — A meaningful share of revenues and expenses is denominated in USD, creating transaction and translation exposure.

- Regulatory changes can delay or block drug development and approvals
- Clinical trial failures can affect safety, data integrity, and timelines
- Supplier and manufacturing issues can disrupt product availability
- IT and cyber incidents can expose data or interrupt operations
- FX and liquidity risk matter because the business has USD exposure

## Accounting

Orexo’s revenue recognition is judgmental because product sales include estimated deductions for discounts, rebates, and returns, and revenue is recognized only when variable consideration is highly probable not to reverse. The company also carries material provisions, inventories, receivables, and lease and borrowing balances, so estimates around collectability, obsolescence, and financing costs can materially affect reported results.

- **Revenue recognition with variable consideration** — Net sales and provisions
- **Inventory valuation and obsolescence** — Cost of goods sold and inventory carrying value
- **Accounts receivable and customer concentration** — Credit losses and working capital
- **Foreign currency accounting** — Financial items and equity
- **Borrowings and lease accounting** — Net financial items and liabilities

- Revenue is net of estimated discounts, rebates, and returns
- Provisions for customer deductions affect reported sales
- Inventory obsolescence testing matters for finished goods and WIP
- Receivables concentration increases credit-loss judgment
- Lease, borrowing, and FX accounting affect balance sheet and earnings

---

*Last updated: 2026-08-11T04:04:55.105528+00:00*